Table 2.
Univariate and multivariate analysis for factors influencing progression free survival (PFS) of patients
| Variables | Progression free survival (PFS) | ||
|---|---|---|---|
| Univariate | Multivariate | ||
| P-value | HR (95%CI) | p-value | |
| Biological Therapy (Yes vs No) | 0.0102 | ||
| AJCC stage (stage III vs stage IV) | 0.0102 | 3.926 (1.578–9.766) | 0.003 |
| Melanoma subtype (Mucosal vs Others) | 0.0368 | ||
| Platelet count (<168.5 vs ≥168.5, ×109/L) | 0.0147 | ||
| PAR (<4.251 vs ≥4.251) | 0.0018 | 0.656 (0.489–0.880) | 0.005 |
| PGR (<4.694 vs ≥4.694) | 0.0065 | ||
Abbreviations: CI, confidence interval; AJCC, American Joint Committee on Cancer; PAR, platelet to albumin ratio; PGR, platelet to globulin ratio.